Imunon (IMNN) Non Operating Income (2010 - 2025)
Imunon's (IMNN) quarterly Non Operating Income came in at $38853.0 in Q4 2025, down 56.32% YoY from $88957.0 in Q4 2024, and down 16.81% on a QoQ basis from $46704.0 in Q3 2025.
Imunon (IMNN) Non Operating Income (2010 - 2025) Analysis & Trends
Imunon (IMNN) has 16 years of Non Operating Income data on file, last reported at $38853.0 in Q4 2025.
- Quarterly Non Operating Income fell 56.32% year-over-year to $38853.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $201819.0 (down 60.6% YoY) and the FY2025 annual result came in at $155666.0, down 69.61% from the prior year.
- Non Operating Income fell to $38853.0 in Q4 2025, from $46704.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $427454.0 in Q3 2023 to a low of -$7.9 million in Q4 2022.
- A 5-year average of -$675214.1 and a median of $26276.0 in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income sank 6813.13% — and 2023, when it jumped 1526.78%.
- Tracing IMNN's Non Operating Income over 5 years: stood at -$113884.0 in 2021, then slumped by 6813.13% to -$7.9 million in 2022, then soared by 97.45% to -$200891.0 in 2023, then surged by 144.28% to $88957.0 in 2024, then tumbled by 56.32% to $38853.0 in 2025.
- The last three Non Operating Income figures came in at $38853.0 (Q4 2025), $46704.0 (Q3 2025), and $27305.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Imunon | 8.42 Mn | 8.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 38,853.00 |
| Sep 30, 2025 | 46,704.00 |
| Jun 30, 2025 | 27,305.00 |
| Dec 31, 2024 | 88,957.00 |
| Sep 30, 2024 | 115,992.00 |
| Jun 30, 2024 | 225,334.00 |
| Mar 31, 2024 | 81,921.00 |
| Dec 31, 2023 | -200,891.00 |
| Sep 30, 2023 | 427,454.00 |
| Jun 30, 2023 | -84,580.00 |
| Mar 31, 2023 | 93,085.00 |
| Dec 31, 2022 | -7.87 Mn |
| Sep 30, 2022 | 26,276.00 |
| Jun 30, 2022 | -64,666.00 |
| Mar 31, 2022 | -4.63 Mn |
| Dec 31, 2021 | -113,884.00 |
| Sep 30, 2021 | -348,968.00 |
| Jun 30, 2021 | -376,995.00 |
| Mar 31, 2021 | -305,659.00 |
| Dec 31, 2020 | -64,115.00 |